- Home
- LOPE vs NUVL Comparison
LOPE vs NUVL Comparison
Compare LOPE & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOPE
- NUVL
- Stock Information
- Founded
- LOPE 1949
- NUVL 2017
- Country
- LOPE United States
- NUVL United States
- Employees
- LOPE N/A
- NUVL N/A
- Industry
- LOPE Other Consumer Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- LOPE Real Estate
- NUVL Health Care
- Exchange
- LOPE Nasdaq
- NUVL Nasdaq
- Market Cap
- LOPE 5.3B
- NUVL 5.6B
- IPO Year
- LOPE 2008
- NUVL 2021
- Fundamental
- Price
- LOPE $168.05
- NUVL $70.25
- Analyst Decision
- LOPE Buy
- NUVL Strong Buy
- Analyst Count
- LOPE 3
- NUVL 10
- Target Price
- LOPE $197.67
- NUVL $113.10
- AVG Volume (30 Days)
- LOPE 217.5K
- NUVL 464.1K
- Earning Date
- LOPE 02-19-2025
- NUVL 02-27-2025
- Dividend Yield
- LOPE N/A
- NUVL N/A
- EPS Growth
- LOPE 13.68
- NUVL N/A
- EPS
- LOPE 7.73
- NUVL N/A
- Revenue
- LOPE $1,033,002,000.00
- NUVL N/A
- Revenue This Year
- LOPE $7.94
- NUVL N/A
- Revenue Next Year
- LOPE $6.19
- NUVL N/A
- P/E Ratio
- LOPE $21.71
- NUVL N/A
- Revenue Growth
- LOPE 7.50
- NUVL N/A
- 52 Week Low
- LOPE $126.17
- NUVL $61.80
- 52 Week High
- LOPE $192.18
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- LOPE 34.40
- NUVL 36.80
- Support Level
- LOPE $165.52
- NUVL $69.95
- Resistance Level
- LOPE $183.55
- NUVL $73.24
- Average True Range (ATR)
- LOPE 5.90
- NUVL 3.27
- MACD
- LOPE -2.01
- NUVL -0.70
- Stochastic Oscillator
- LOPE 9.49
- NUVL 29.13
About LOPE Grand Canyon Education Inc.
Grand Canyon Education, Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's most significant university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases and certificates across nine colleges both online, on ground at its campus in Phoenix, Arizona and at four off-site classroom and laboratory sites. The Company generates all of its revenue through services agreements with its university partners.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.